CXU liquid-to-gel scaffold regeneration targets multiple markets.
CNXU’s CXU single liquid-to-gel formulation targets scaffold-driven tissue regeneration, with a platform planned across wound care, aesthetics, dental, veterinary, and 3D bioprinting.
CXU is positioned as an ECM scaffold-mimicking, liquid-to-gel tissue matrix meant to restore regeneration rather than scar formation. The company frames $20+ billion combined addressable market potential and targets wound-care 510(k) entry in 2027–2028, while remaining pre-clinical and not yet FDA-cleared.
"This Stock Looks Like The Next 10-Bagger"